Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd maintains a strong liquidity position, as evidenced by a current ratio of 4.71, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. The company's liquidity_fpt score is high, reflecting its robust cash flow generation and minimal long-term debt obligations. The operating cash flow of 930,155,000 INR and free cash flow of 723,958,000 INR further support its liquidity strength. In terms of profitability, Lincoln Pharmaceuticals Ltd demonstrates a return on equity (ROE) of 0.1226 and a return on assets (ROA) of 0.1033, which are strong indicators of the company's ability to generate profits from its equity and total assets. These metrics suggest that the company is effectively utilizing its resources to generate returns, which is in line with the preferred metrics for the pharmaceutical industry. The company's revenue is distributed across various geographic regions, including Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. This geographic diversification helps mitigate the risk of over-reliance on any single market. However, the company's revenue concentration in specific regions is not disclosed, which could impact its exposure to regional economic fluctuations. Lincoln Pharmaceuticals Ltd has shown a consistent growth trajectory, with a strong operating income of 886,300,000 INR and a net income of 823,464,000 INR. The company's capital expenditure of -192,442,000 INR indicates a reduction in investment in fixed assets, which could be a strategic move to optimize capital usage. The outlook for the current fiscal year and the next fiscal year is positive, with the company expected to maintain its growth momentum. The risk assessment for Lincoln Pharmaceuticals Ltd indicates a low liquidity risk and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is characterized by minimal long-term debt. The dilution potential is low, as the number of shares outstanding remains unchanged between basic and diluted shares. The company's strong cash flow and low debt levels contribute to its favorable risk profile. Recent events and filings for Lincoln Pharmaceuticals Ltd do not indicate any significant changes in the company's operations or financial position. The company's last actual EPS was 41.11 INR, and the last actual revenue was 6,232,301,000 INR. Analyst estimates suggest a mean recommendation of 2.00, with one buy recommendation and no strong buy, hold, sell, or strong sell recommendations. This indicates a generally positive outlook from analysts, although there is no strong consensus for aggressive investment.